Bleeding Disorder Treatment Market Size, Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Russia, Japan, China, India, Australia, Brazil, Mexico, Saudi Arabia, South Africa, UAE), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025

Bleeding Disorder Treatment Market size is projected to experience significant growth from 2019 to 2025.
 

The growing prevalence of bleeding disorders globally will act as a primary driver for the growth of the bleeding disorder treatment market. The majority of bleeding conditions are inherited but some are acquired due to side effects of certain medications, vitamin K deficiency, liver diseases, low red blood cell count, and others. The rising incidences of causative factors leading to bleeding disorder will stimulate the demand for treatment over the forecast timeframe.   
 

The increasing number of people suffering from anemia, liver diseases, and blood coagulating conditions will drive bleeding disorder treatment market size. Increasing awareness about bleeding conditions, especially hemophilia, coupled with numerous government initiatives to establish a wide network of bleeding disorder diagnosis and treatment centers will support industry expansion over the coming years.
 

High investments in R&D activities pertaining to the development of recombinant factors along with improvements in the technology used for treating bleeding conditions will drive industry growth over the forecast period. However, the shortage of skilled healthcare professionals and the high cost of medications will restrain industry growth to a certain extent over the coming years.   
 

Based on type, the industry is bifurcated into Hemophilia A, Hemophilia B, Von Willebrand disease, and others. The Hemophilia A market dominated the industry in 2018 due to the high prevalence rate coupled with the rising awareness about disease treatment and medications available in the market for hemophilia type A.
 

The drug class segment includes recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, antifibrinolytic, desmopressin, fibrin sealants, and others. Lower infection risks and high investments in research and development by industry players will lead to high growth of the recombinant coagulation factor concentrates market over the coming years.

The U.S. dominated the North America bleeding disorder treatment industry in 2018 owing to the high prevalence of bleeding disorders coupled with favorable insurance and reimbursement policies in the country. According to the Hemophilia Federation of America, nearly 400 newborn babies are annually diagnosed with hemophilia in the U.S. thereby increasing the demand for treatment.
 

India bleeding disorder treatment market is estimated to witness lucrative growth over the analysis period. The rising awareness regarding bleeding disorders and the availability of medications to treat these conditions will drive the Indian bleeding disorder treatment market. Several initiatives undertaken by the government to build the necessary healthcare infrastructure will positively impact industry growth.
 

Sanofi SA, Swedish Orphan Biovitrum AB, Janssen Global Services, Baxter International, Pfizer, Genentech, CSL Behring, Novo Nordisk, Biogen, Bayer AG, Alnylam Pharmaceuticals, Bristol-Myers Squibb Company, Xenetic Biosciences, Amgen, and Bioverativ are some of the major industry players functional in the market. Companies are currently investing in R&D to develop an appropriate and superior treatment for bleeding disorders to increase their market share as well as to expand the product portfolio of the company.
 

Bleeding Disorder Treatment Market by Type, 2014-2025 (USD Million)

• Hemophilia A
• Hemophilia B
• Von Willebrand disease
• Others

Bleeding Disorder Treatment Market by Drug Class, 2014-2025 (USD Million)

• Recombinant coagulation factor concentrates
• Plasma-derived coagulation factor concentrates
• Antifibrinolytic
• Desmopressin
• Fibrin sealants
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Others
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Others

Company Profiles:

• Sanofi SA
• Swedish Orphan Biovitrum AB
• Janssen Global Services
• Baxter International
• Pfizer
• Genentech
• CSL Behring
• Novo Nordisk
• Biogen
• Bayer AG
• Alnylam Pharmaceuticals
• Bristol-Myers Squibb Company
• Xenetic Biosciences
• Amgen
• Bioverativ 

What Information does this report contain?